Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Eur J Pharmacol
2013 Nov 15;7201-3:264-75. doi: 10.1016/j.ejphar.2013.10.018.
Show Gene links
Show Anatomy links
Similar activity of mecamylamine stereoisomers in vitro and in vivo.
Papke RL
,
Stokes C
,
Muldoon P
,
Imad Damaj M
.
???displayArticle.abstract???
A previous characterization of mecamylamine stereoisomers using nicotinic acetylcholine receptors expressed in Xenopus oocytes revealed only small differences between the activity of the R and S forms of mecamylamine. However, that work was limited in the breadth of receptor subtypes tested, especially in regard to the discrimination of high and low sensitivity receptors, which differ in the ratios of alpha and beta subunits. We report new data using subunit concatamers, which produce uniform populations of high-sensitivity or low-sensitivity receptors, as well as alpha2, alpha5, and alpha6-containing receptors, which were not studied previously. Consistent with previous studies, we found that beta4-containing receptors were most sensitive to mecamylamine and that the IC50 values for the inhibition of net charge were lower than for inhibition of peak currents. No large differences were seen between the activities of the mecamylamine isomers. Additionally, a previously reported potentiation of high-sensitivity α4β2 receptors by S-mecamylamine could not be reproduced in the oocyte system, even with mutants that had greatly reduced sensitivity to mecamylamine inhibition or when the selective agonist TC-2559 was used. In vivo studies suggested that the R-isomer might be somewhat more potent than the S isomer at blocking CNS effects of nicotine. Although the potency difference was no more than a factor of two, it is consistent with lower LD50 estimates previously reported for the R isomer. Our results significantly extend knowledge of the nicotinic acetylcholine receptor activity profile of mecamylamine and support the hypothesis that these effects are not strongly stereoisomer selective.
Benowitz,
Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics.
2009, Pubmed
Benowitz,
Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics.
2009,
Pubmed
Chini,
Neuronal-type alpha-bungarotoxin receptors and the alpha 5-nicotinic receptor subunit gene are expressed in neuronal and nonneuronal human cell lines.
1992,
Pubmed
Coe,
Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.
2005,
Pubmed
,
Xenbase
DENNIS,
Mecamylamine in the treatment of hypertension.
1957,
Pubmed
Damaj,
Pharmacological characterization of nicotine-induced seizures in mice.
1999,
Pubmed
Damaj,
Involvement of calcium and L-type channels in nicotine-induced antinociception.
1993,
Pubmed
Damaj,
In vivo pharmacological effects of dihydro-beta-erythroidine, a nicotinic antagonist, in mice.
1995,
Pubmed
Fedorov,
Differential pharmacologies of mecamylamine enantiomers: positive allosteric modulation and noncompetitive inhibition.
2009,
Pubmed
Fowler,
Habenular α5 nicotinic receptor subunit signalling controls nicotine intake.
2011,
Pubmed
Frahm,
Aversion to nicotine is regulated by the balanced activity of β4 and α5 nicotinic receptor subunits in the medial habenula.
2011,
Pubmed
,
Xenbase
Gotti,
Structural and functional diversity of native brain neuronal nicotinic receptors.
2009,
Pubmed
Han,
Localization of [3H]nicotine, [3H]cytisine, [3H]epibatidine, and [125I]alpha-bungarotoxin binding sites in the brain of Macaca mulatta.
2003,
Pubmed
Han,
Localization of nAChR subunit mRNAs in the brain of Macaca mulatta.
2000,
Pubmed
Harpsøe,
Unraveling the high- and low-sensitivity agonist responses of nicotinic acetylcholine receptors.
2011,
Pubmed
Jackson,
The α3β4* nicotinic acetylcholine receptor subtype mediates nicotine reward and physical nicotine withdrawal signs independently of the α5 subunit in the mouse.
2013,
Pubmed
Jackson,
Role of alpha5 nicotinic acetylcholine receptors in pharmacological and behavioral effects of nicotine in mice.
2010,
Pubmed
Kuryatov,
Roles of accessory subunits in alpha4beta2(*) nicotinic receptors.
2008,
Pubmed
Kuryatov,
Expression of functional human α6β2β3* acetylcholine receptors in Xenopus laevis oocytes achieved through subunit chimeras and concatamers.
2011,
Pubmed
,
Xenbase
Lindsley,
(S)-(+)-mecamylamine (TC-5214): a neuronal nicotinic receptor modulator enters phase III trials as an adjunct treatment for Major Depressive Disorder (MDD).
2010,
Pubmed
Lukas,
Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.
2010,
Pubmed
Marubio,
Reduced antinociception in mice lacking neuronal nicotinic receptor subunits.
1999,
Pubmed
Millar,
Diversity of vertebrate nicotinic acetylcholine receptors.
2009,
Pubmed
Miller,
Genetic manipulation of ion channels: a new approach to structure and mechanism.
1989,
Pubmed
Mineur,
Cytisine-based nicotinic partial agonists as novel antidepressant compounds.
2009,
Pubmed
,
Xenbase
Papke,
Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes.
2001,
Pubmed
,
Xenbase
Papke,
The pharmacological activity of nicotine and nornicotine on nAChRs subtypes: relevance to nicotine dependence and drug discovery.
2007,
Pubmed
,
Xenbase
Papke,
Extending the analysis of nicotinic receptor antagonists with the study of alpha6 nicotinic receptor subunit chimeras.
2008,
Pubmed
,
Xenbase
Papke,
Tricks of perspective: insights and limitations to the study of macroscopic currents for the analysis of nAChR activation and desensitization.
2010,
Pubmed
,
Xenbase
Papke,
Activation and inhibition of mouse muscle and neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes.
2010,
Pubmed
,
Xenbase
Papke,
The nicotinic acetylcholine receptors of zebrafish and an evaluation of pharmacological tools used for their study.
2012,
Pubmed
,
Xenbase
Rabenstein,
The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not beta2- or alpha7-nicotinic acetylcholine receptor subunit knockout mice.
2006,
Pubmed
Rollema,
Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence.
2010,
Pubmed
,
Xenbase
Rose,
Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy.
1998,
Pubmed
Sanberg,
Treatment of Tourette's syndrome with mecamylamine.
1998,
Pubmed
Silver,
Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette's disorder.
2001,
Pubmed
Singh,
Mecamylamine (Targacept).
2006,
Pubmed
Stokes,
Use of an α3β4 nicotinic acetylcholine receptor subunit concatamer to characterize ganglionic receptor subtypes with specific subunit composition reveals species-specific pharmacologic properties.
2012,
Pubmed
,
Xenbase
Suchocki,
Synthesis of 2-exo- and 2-endo-mecamylamine analogues. Structure-activity relationships for nicotinic antagonism in the central nervous system.
1991,
Pubmed
Timmermann,
Augmentation of cognitive function by NS9283, a stoichiometry-dependent positive allosteric modulator of α2- and α4-containing nicotinic acetylcholine receptors.
2012,
Pubmed
,
Xenbase
Wada,
Distribution of alpha 2, alpha 3, alpha 4, and beta 2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat.
1989,
Pubmed
,
Xenbase
Webster,
Antagonist activities of mecamylamine and nicotine show reciprocal dependence on beta subunit sequence in the second transmembrane domain.
1999,
Pubmed
,
Xenbase
Zhou,
Human alpha4beta2 acetylcholine receptors formed from linked subunits.
2003,
Pubmed
,
Xenbase
Zwart,
5-I A-85380 and TC-2559 differentially activate heterologously expressed alpha4beta2 nicotinic receptors.
2006,
Pubmed
,
Xenbase
